Partner David Rosen was quoted in a Washington Post article, “Regulators Take a Growing Interest in Drugmakers’ Moves to Protect Profits,” on March 19, 2015. The article discussed the competitive nature of patents for the prescription drug market, along with related antitrust issues. Rosen was quoted saying, “This industry is under a lot of scrutiny because the cost savings in the generic world are pretty high for the public.”
People
Related News
December 29, 2025
In the News
Matt Kiel Featured by Los Angeles Business Journal – 'Keep pressing forward and doing your best'
Foley & Lardner LLP senior counsel Matt Kiel is featured by Los Angeles Business Journal for his career journey in the article, “Matt Kiel's Steady Climb.”
December 26, 2025
In the News
Louis Lehot Shares 2026 M&A Outlook on Financing, Exits, and Key Trends
Foley & Lardner LLP partner Louis Lehot was featured in the Mergers & Acquisitions' week-long series, “The 2026 M&A Outlook.”
December 24, 2025
In the News
Kyle Faget on HHS Gender-Affirming Care Declaration – Impact is 'Enormous'
Foley & Lardner LLP partner Kyle Faget commented on the recent Department of Health and Human Services declaration rejecting gender-affirming care in the STAT News article, “Nineteen states, D.C. sue HHS over gender-affirming care crackdown."